Lexicon Pharmaceuticals (LXRX) versus Its Rivals Financial Analysis
Lexicon Pharmaceuticals (NASDAQ: LXRX) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Lexicon Pharmaceuticals to related businesses based on the strength of its earnings, dividends, institutional ownership, profitability, risk, valuation and analyst recommendations.
Valuation & Earnings
This table compares Lexicon Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Lexicon Pharmaceuticals||$83.34 million||-$141.42 million||-8.30|
|Lexicon Pharmaceuticals Competitors||$284.28 million||$34.29 million||74.13|
Risk & Volatility
Lexicon Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals’ competitors have a beta of 8.49, suggesting that their average stock price is 749% more volatile than the S&P 500.
This table compares Lexicon Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Lexicon Pharmaceuticals Competitors||-5,312.21%||-433.82%||-39.43%|
This is a summary of recent recommendations and price targets for Lexicon Pharmaceuticals and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Lexicon Pharmaceuticals Competitors||852||3200||11603||231||2.71|
Lexicon Pharmaceuticals presently has a consensus target price of $28.50, indicating a potential upside of 172.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.76%. Given Lexicon Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than its competitors.
Institutional & Insider Ownership
50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.8% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.